Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ versus SPECTRACEF.
FORTAZ vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic